Sitagliptin in the treatment of type 2 diabetes: a meta‐analysis

@article{Zhan2012SitagliptinIT,
  title={Sitagliptin in the treatment of type 2 diabetes: a meta‐analysis},
  author={M. Zhan and T. Xu and Fengbo Wu and Y. Tang},
  journal={Journal of Evidence‐Based Medicine},
  year={2012},
  volume={5}
}
  • M. Zhan, T. Xu, +1 author Y. Tang
  • Published 2012
  • Medicine
  • Journal of Evidence‐Based Medicine
  • Objective: To evaluate the benefits and harms of sitagliptin in people with type 2 diabetes mellitus. 
    13 Citations
    DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews
    • 4
    Assessment of β-Cell Function
    COMT 158G/A and CYP1B1 432C/G polymorphisms increase the risk of endometriosis and adenomyosis: a meta-analysis.
    • 13

    References

    SHOWING 1-10 OF 28 REFERENCES
    Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
    • 298
    Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes *
    • 274
    Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
    • 151
    Treatment options for type 2 diabetes: introducing the incretin-based therapies
    • 3
    • PDF
    Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
    • 86